CPT 81337 SMN1 Family Test Reimbursement

CPT code 81337 denotes a molecular laboratory test that detects family-specific genetic variants in the survival of motor neuron 1 (SMN1) gene. This targeted assay is used when there is a known familial SMN1 variant to determine whether the patient carries the same change. Nationally, such testing informs diagnosis, carrier status assessment, and clinical management decisions for conditions related to SMN1 alterations.

Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context for SMN1 family-specific testing, typical sites of service, and what payers commonly consider when covering targeted genetic tests. The publication summarizes coverage considerations, common billing modifiers and service-line placement, and offers benchmarking context where available.

This summary outlines the role of CPT code 81337 in precision genetic diagnostics, highlights payer relevance for reimbursement and prior authorization pathways, and provides operational context for laboratories and billing staff handling family-specific SMN1 testing. Data not available in the input are noted where applicable in detailed sections.

Billing Code Overview

CPT code 81337 describes a laboratory technical procedure that detects specific changes in the survival of motor neuron 1 (SMN1) gene, targeting genetic variants known to occur within a patient’s family. The service is a molecular genetic test focused on family-specific variant detection for the SMN1 gene.

Service Type: Molecular genetic diagnostic testing

Typical Site of Service: Clinical molecular laboratory or hospital laboratory performing genetic testing

Clinical Context

A patient with a family history of spinal muscular atrophy (SMA) is referred for targeted genetic testing of the survival motor neuron 1 gene. Typical patients include symptomatic infants or children with developmental delay or hypotonia, adult relatives seeking carrier status confirmation, or prenatal/ preconception counselees where a known familial SMN1 pathogenic variant exists. The clinical workflow begins with genetic counseling and informed consent, collection of a blood or buccal sample, and submission to a molecular diagnostics laboratory specifying testing for the known family-specific SMN1 variant. The laboratory performs targeted molecular analysis (such as allele-specific PCR, MLPA for exon dosage, or targeted sequencing) to detect the specific familial change. Results are reviewed by the laboratory director and communicated to the ordering clinician and genetic counselor for interpretation, family cascade testing, and care planning when applicable.

Coding Specifications

Modifier	Description	When to Use
`26`	Professional component	Use when billing only the professional interpretation component separate from the technical laboratory testing (rare for most single-source molecular labs).
`TC`	Technical component

Taxonomy Code	Specialty	Notes
2080P0800X	Medical Genetics	Physicians who order and interpret genetic testing for inherited neuromuscular disorders.
2085R0200X	Genetic Counseling	Certified genetic counselors who provide pre- and post-test counseling and coordinate family testing.
207RG0100X	Neurology	Pediatric and adult neurologists who evaluate patients with hypotonia, motor delay, or suspected neuromuscular disease.
207L00000X	Pathology - Molecular Genetics	Laboratory directors and molecular pathologists overseeing test validation and result sign-out.
207LP2900X	Clinical Laboratory	Clinical laboratory technologists and directors performing and billing technical components of genetic tests.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`G12.0`	Infantile spinal muscular atrophy, type I [Werdnig-Hoffmann]	Direct diagnosis of SMA where SMN1 targeted testing confirms causative genetic variants.
`G12.1`	Other inherited spinal muscular atrophy	Covers other hereditary SMA types where SMN1 testing is relevant for diagnosis.
`R62.0`	Delayed milestone in childhood	Symptom-based reason to order SMN1 testing in infants and young children with motor delays.
`R29.898`	Other symptoms and signs involving the nervous and musculoskeletal systems	Used when nonspecific neuromuscular symptoms prompt targeted genetic testing.
`Z14.8`	Genetic carrier status and genetic counseling (other specified carrier)	Used when asymptomatic individuals seek carrier testing for a known familial SMN1 variant.
`Z33.1`	Pregnant state, incidental — genetic testing in pregnancy	Used when prenatal or preconception testing is performed to determine fetal or parental carrier status for SMN1 variants.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`81220`	SMN1 (survival motor neuron 1) gene analysis; common deletion/duplication analysis (e.g., exon-level copy number)	Often performed alongside targeted familial variant testing to assess exon deletions or SMN1 copy number status when broader copy number information is required.
`81335`	SMN2 (survival motor neuron 2) gene analysis; quantification or variant analysis	Performed when phenotypic severity prediction or therapeutic considerations require assessment of SMN2 copy number in SMA evaluation.
`81479`	Unlisted molecular pathology procedure	Used when a specific targeted familial variant test or unique method does not have a direct CPT descriptor and additional billing guidance is needed.
`G0452`	Laboratory test handling or specialty molecular test (Medicare laboratory code)	May be used for Medicare administrative tracking or when specific lab test handling codes are required in workflow.
`83020`	Hemoglobin; electrophoresis or other protein analysis — example laboratory correlate (not specific to SMN)	Occasionally billed in the same laboratory encounter when multiple genetic or laboratory evaluations are performed on the same specimen set; included as a general example of ancillary lab tests.

OpenPayer

Summary & Overview

CPT 81337: SMN1 Family-Specific Genetic Test